Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate

Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate and pregnancy

Not Recommended

• Fetal development
• Absorbed into the body
• Hormone disruptor

This ingredient is a perfluorinated compound (PFAS), part of a chemical class known as 'forever chemicals' due to their environmental persistence. PFAS are used in cosmetics as surfactants and film-formers to improve product texture and water resistance. Studies have found associations between PFAS exposure during pregnancy and adverse outcomes including lower birth weight, preeclampsia, and altered fetal development. According to research published in environmental health journals, PFAS can cross the placental barrier and accumulate in fetal tissues. The persistent nature of these chemicals means they bioaccumulate in the body over time. While specific data on this particular PFAS variant is limited, the chemical structure suggests similar concerns to other perfluorinated compounds. ECHA has proposed restrictions on PFAS in cosmetics, and several European countries are moving toward bans. The American College of Obstetricians and Gynecologists (ACOG) recommends that pregnant women minimize exposure to potential endocrine disruptors. Many obstetricians advise avoiding PFAS-containing products during pregnancy as a precautionary measure given the known risks of related compounds and the lack of safety data.

Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate and breastfeeding

Not Recommended

• Passes into breast milk
• Infant exposure

As a perfluorinated compound, this ingredient belongs to the PFAS family of chemicals that are highly persistent and bioaccumulative. PFAS have been extensively studied in breastfeeding contexts, with research consistently showing transfer into breast milk. Studies published in Environmental Health Perspectives and other journals have detected PFAS in breast milk samples, with concentrations correlating to maternal exposure levels. PFAS can remain in the body for years and continue to be transferred to breastfed infants. Research has linked infant PFAS exposure to immune system effects and developmental concerns. While this specific variant lacks direct studies, its chemical structure suggests similar bioaccumulation and transfer potential. Health organizations including the AAD and environmental health experts recommend that breastfeeding mothers minimize PFAS exposure. The persistent nature of these chemicals means they can accumulate during product use and continue transferring to breast milk long after exposure. Most dermatologists advise avoiding PFAS-containing cosmetics during the breastfeeding period.

Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate and postpartum

Caution Advised

• Endocrine disruptor
• Environmental pollutant

This perfluorinated compound (PFAS) poses concerns related to bioaccumulation and potential endocrine disruption. For postpartum women not breastfeeding, the immediate infant transfer concern is absent, but personal health and future fertility considerations remain. PFAS compounds persist in the body for years and have been associated with hormonal effects, immune system impacts, and other health concerns in adult women. Environmental health experts note that PFAS exposure during the postpartum period could affect future pregnancies if the chemicals remain in the body. The regulatory trend toward restricting PFAS in cosmetics reflects growing recognition of these persistent chemicals' long-term health implications.

Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate and trying to conceive

Not Recommended

• Fertility effects
• Hormone disruptor
• Builds up in tissue

This perfluorinated compound (PFAS) is part of a chemical class that has raised concerns for women trying to conceive due to bioaccumulation and potential effects on fertility and early pregnancy outcomes. Research has found associations between PFAS exposure and longer time to pregnancy, reduced fertility, and increased risk of pregnancy complications. PFAS persist in the body for years, meaning exposure while trying to conceive can affect early fetal development after conception. Studies suggest PFAS may interfere with reproductive hormones and implantation. Fertility specialists often recommend minimizing exposure to potential endocrine disruptors including PFAS during the preconception period to optimize conditions for conception and early pregnancy.

Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate and PCOS

Caution Advised

• Interferes with hormones
• Endocrine disruptor

This ingredient is a perfluorinated compound (PFAS), a class of chemicals that has shown potential for endocrine disruption in research studies. Women with PCOS have existing hormonal imbalances, making them potentially more sensitive to compounds that could interfere with hormone function. Research published in endocrinology journals has found associations between PFAS exposure and altered reproductive hormone levels, insulin resistance, and metabolic effects. While this specific variant lacks direct PCOS studies, the chemical class has shown concerning patterns. Some studies suggest PFAS may affect androgen levels and metabolic function, both of which are already disrupted in PCOS. Given the potential for hormonal interference and the lack of safety data specific to PCOS, many healthcare providers recommend that women with hormonal conditions minimize exposure to endocrine-disrupting chemicals including PFAS. Choosing PFAS-free products may be a prudent approach for managing PCOS alongside other lifestyle factors.

Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate and general use

Caution Advised

• Endocrine disruptor
• Environmental pollutant

This ingredient belongs to the PFAS (per- and polyfluoroalkyl substances) family, commonly called 'forever chemicals' due to their extreme environmental persistence. PFAS are used in cosmetics as surfactants and film-formers for their water-resistant properties. Growing research has linked PFAS exposure to various health concerns including endocrine disruption, immune system effects, and bioaccumulation. These chemicals do not break down in the environment or human body, persisting for years and accumulating with repeated exposure. The European Chemicals Agency (ECHA) has proposed restrictions on PFAS in cosmetics due to environmental and health concerns. Several European countries including Denmark and Sweden are implementing bans on PFAS in cosmetics. While the FDA has not restricted PFAS in personal care products, environmental health organizations recommend minimizing exposure when possible. Many cosmetic companies are voluntarily reformulating to remove PFAS. Consumers can look for 'PFAS-free' labels or choose products with simpler, plant-based ingredient lists.

Everything else flagged for the same profiles

• Flagged in pregnancy
• Flagged in breastfeeding
• Flagged in trying to conceive
• Flagged in postpartum
• Flagged in PCOS

Related ingredients

Ingredients suggested in place of Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate, each one with its own page here.

• Glycerin

Ingredients that raise the same concerns.

• Perfluorooctyl TriethoxysilaneEnvironmental pollutant, Endocrine disruptor, Builds up in tissue
• PerfluorohexaneEnvironmental pollutant, Endocrine disruptor, Builds up in tissue
• Polyperfluoromethylisopropyl EtherEnvironmental pollutant, Endocrine disruptor, Builds up in tissue
• Ammonium C6-16 Perfluoroalkylethyl PhosphateEnvironmental pollutant, Endocrine disruptor, Builds up in tissue
• PerfluorodecalinEnvironmental pollutant, Endocrine disruptor, Builds up in tissue
• PerfluoroperhydrophenanthreneEnvironmental pollutant, Endocrine disruptor, Builds up in tissue

Where this came from

Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.

Assessment last pulled from the ingredient database on 15 September 2026.